This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Sep 2026 consolidated quarter: revenue up 652%, profit after tax up 435% year on year
SHUKRAPHAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations was Rs 44.20 crore versus Rs 5.88 crore in the same quarter of 2025, a 652% rise, while profit after tax was Rs 12.71 crore versus Rs 2.38 crore, a 435% rise. Operating profit before interest, tax, depreciation and other income improved from negative 7.1% of revenue to 42.3%. Consolidated half-year operating cash flow was Rs 0.43 crore.
Strong growth supports the stock, but weak cash conversion and higher borrowings may limit shareholder gains.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹44.20 Cr against ₹5.88 Cr a year ago, about 8× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.